ArticleJTO clinical and research reports2026
ALK Inhibitor Response in Novel
Article in JTO clinical and research reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- RareJTO clinical and research reports · 2026Article
- Case Report: Complete response and prolonged survival to alectinib in a NSCLC patient with metastases harboring a rareFrontiers in oncology · 2026Article
Corrections and comments
- Commented on byRare2026
Authors and funding
6 authors.
Funding
Abstract
Background: Case Presentation: We report two patients with metastatic NSCLC harboring novel Conclusions: These cases expand the landscape of noncanonical
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.